Voxy review

Voxy does the disclosure this category almost never does: its compliance page names VialsRX of Houston as the 503A compounding pharmacy, with a street address and phone number, and names Arora Health & Aesthetics, LLC as the prescribing medical group. Both can be checked independently. Its sermorelin copy is also accurate rather than hyped — it describes stimulating your own growth hormone rather than supplying synthetic HGH. What it does not have is a terms of service page at any standard path, a published refund policy, a state list, or any price at all for sermorelin or NAD⁺, both of which sit beside a fully published GLP-1 price ladder.

Voxy is a Scottsdale, Arizona telehealth practice offering four treatments: compounded semaglutide, compounded tirzepatide, injectable NAD⁺ and sermorelin. It publishes a Scottsdale street address and a staffed phone number, and a HIPAA Notice of Privacy Practices. Its compliance page names VialsRX (Houston, Texas) as a licensed compounding pharmacy partner and describes it as 503A, and names Arora Health & Aesthetics, LLC as the medical group, with an explicit disclaimer that inclusion denotes a professional collaboration rather than a joint venture.

A free assessment with no charge to see whether you qualify, no labs required to start, and care managed by a licensed nurse practitioner who is not named individually — provider details are stated to be available during your consultation. The transparency stack is what distinguishes this practice and it is worth being specific about why: naming both the pharmacy that makes the vial and the medical group that writes the script gives you two independent entities you can look up, which is categorically stronger than a badge that only certifies the website. Against that sits a compliance gap that is hard to explain away for a company this careful elsewhere. There is no terms of service page at /terms, /terms-of-service, /terms-of-use or /tos — all return not-found — which means no published refund policy, no governing law and no arbitration position, and the only commitment language anywhere is "cancel anytime". The footer claims availability nationwide while the site simultaneously states that services are available only where affiliated providers are licensed and pharmacy partners are authorized to dispense, so the nationwide claim is not a verified state list. No LegitScript certification or pharmacy accreditation seal appears.

Complete on one line of the business and absent on the other, and the absent one is the longevity line. Voxy publishes a four-tier price ladder for both GLP-1 medications — semaglutide at $179 month-to-month down to $129 on a twelve-month prepay, tirzepatide at $299 down to $199 — with the inclusions listed plainly: medication if prescribed, all injection supplies, free discreet shipping, ongoing check-ins and dose adjustments, messaging with the care team, no hidden fees. That is a genuinely good pricing page. Then sermorelin and injectable NAD⁺ are presented as treatments with descriptive copy and no figure at all, so you cannot know what either costs before an intake. Note also that the site's own "starting at $129/mo" headline is the twelve-month prepay tier on the semaglutide line, not a month-to-month rate — a useful signal about how it prices, and a reason to ask specifically whether sermorelin and NAD⁺ carry the same prepay structure before you assume the first number you are quoted is monthly.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, and the plans page's reference to a 503A licensed pharmacy describes the facility's regulatory category rather than any approval of the preparation. On the evidence, both sermorelin and NAD⁺ are weaker than the marketing around them. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone — the site's own framing, and it is accurate, which is more than most sermorelin copy manages — but the long-term human outcome data behind claims about sleep, lean muscle and recovery remains thin beyond short-term IGF-1 movement. Injected NAD⁺ has no controlled human outcome trials at all; the NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials reliably demonstrate is a raised blood NAD⁺ level rather than the mental clarity, energy and cellular repair the product copy describes. Individual results vary.